Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Anderlecht – page 20

433 clinical trials in Anderlecht, Belgium across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Anderlecht at a glance
433
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

433 trials in Anderlecht

Open in trial search

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Hepatic cirrhosis+2

Not recruiting

Study of VS-01 with different treatment times compared to standard care alone in patients with overt hepatic encephalopathy and liver cirrhosis complications

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Citric Acid, Anhydrous Ph. Eur.
  • Sponsor:Versantis AG

Chronic kidney disease

Not recruiting

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hidradenitis

Not recruiting

Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Breast cancer+2

Not recruiting

Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab
  • Sponsor:Institut Jules Bordet

Colonoscopy

Not recruiting

Efficacy and Safety of Mannitol Compared to Plenvu for Bowel Preparation in Patients Undergoing Elective Colonoscopy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Macrogol 4000
  • Sponsor:Ntc S.r.l.

Bronchopulmonary aspergillosis

Not recruiting

Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rezafungin Acetate
  • Sponsor:Mundipharma Research Limited

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Lipoedema

Not recruiting

Study on the Use of Indocyanine Green to Assess Lymphatic Vessel Porosity in Women with Lipedema

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Indocyanine Green
  • Sponsor:Universite Libre de Bruxelles

Bladder transitional cell carcinoma

Not recruiting

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Hepatitis D+1

Not recruiting

Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Anderlecht

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials investigating new treatments for various cancers, including bladder cancer, acute myeloid leukemia, and advanced breast cancer. Studies focus on innovative combination therapies and targeted treatments.

  • Non-muscle invasive bladder cancer therapy
  • Metastatic breast cancer treatments
  • Gastroesophageal cancer interventions
02 Immunology and Inflammatory Conditions

Clinical investigations targeting chronic inflammatory conditions and autoimmune disorders, including Crohn's Disease, Ulcerative Colitis, and Psoriatic Arthritis.

  • Inflammatory bowel disease therapies
  • Novel arthritis treatments
  • Sjögren's Disease interventions
03 Infectious Diseases

Studies examining innovative approaches to combat various infections, including urinary tract infections and viral diseases. Research includes vaccine development and antimicrobial therapies.

  • UTI vaccine development
  • RSV vaccination studies
  • Hepatitis D treatments
04 Cardiovascular and Pulmonary Studies

Research focusing on pulmonary hypertension and cardiovascular disease management, with emphasis on innovative therapeutic approaches and disease prevention.

  • Pulmonary arterial hypertension treatments
  • Cardiovascular disease interventions
  • Post-cardiac arrest care
Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.